• Explore /
  • Poster
  • / Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced <i>BRAF-</i>mutant colorectal cancer (<i>BRAFm </i>CRC).

Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).

Abstract Poster

Authors

Josep Tabernero

Josep Tabernero

Vall d'Hebron Institute of Oncology, Barcelona, Spain

Josep Tabernero , Robin Van Geel , Tormod Kyrre Guren , Rona D. Yaeger , Anna Spreafico , Jason Edward Faris , Takayuki Yoshino , Yasuhide Yamada , Tae Won Kim , Johanna C. Bendell , Martin H. Schuler , Heinz-Josef Lenz , Ferry Eskens , Jayesh Desai , Howard S. Hochster , Emin Avsar , Tim Demuth , Victor Sandor , Elena Elez , Jan H.M. Schellens

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01719380

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3544)

DOI

10.1200/JCO.2016.34.15_suppl.3544

Abstract #

3544

Poster Bd #

241

Abstract Disclosures

Similar Posters

First Author: Robin Van Geel

First Author: Chetan Vakkalagadda

First Author: Eiji Shinozaki

First Author: Gargi Dan Basu